Absci Corp Net Assets
Absci Corp net assets. Based on the latest financial reports, Absci Corp (ABSI) has net assets worth $246.13 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($268.92 Million) and total liabilities ($22.79 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Absci Corp annual equity growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $246.13 Million |
| % of Total Assets | 91.53% |
| Annual Growth Rate | N/A |
| 5-Year Change | -48.25% |
| 10-Year Change | N/A |
| Growth Volatility | 184.56 |
Net Assets of Absci Corp (2019–2025)
Net assets of Absci Corp from 2019 to 2025. This chart illustrates how Absci Corp's net assets have evolved over time, based on quarterly financial data. See Absci Corp balance sheet independence to measure how much of total assets are equity-financed.
Annual Net Assets for Absci Corp (2019–2025)
The table below shows the annual net assets of Absci Corp from 2019 to 2025. For live market cap and overall valuation, see ABSI stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $189.45 Million | +5.76% |
| 2024-12-31 | $179.13 Million | +1.68% |
| 2023-12-31 | $176.18 Million | -35.80% |
| 2022-12-31 | $274.41 Million | -25.05% |
| 2021-12-31 | $366.11 Million | +446.39% |
| 2020-12-31 | $67.00 Million | +262.80% |
| 2019-12-31 | $-41.16 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Absci Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 58340800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Absci Corp Net Assets Breakdown (December 2025)
Absci Corp net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $15.00K | 0.01% |
| Other Comprehensive Income | $591.00K | 0.31% |
| Other Components | $813.63 Million | 429.47% |
| Total Equity | $189.45 Million | 100.00% |
Absci Corp Competitors by Market Cap
The table below lists competitors of Absci Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Concord Biotech Limited
NSE:CONCORDBIO
|
$1.41 Billion |
|
Ultragenyx
NASDAQ:RARE
|
$1.41 Billion |
|
Eastern Communications Co Ltd A
SHG:600776
|
$1.41 Billion |
|
Vestjysk Bank A/S
CO:VJBA
|
$1.41 Billion |
|
Shanghai DaZhong Public Utilities Group Co Ltd
SHG:600635
|
$1.41 Billion |
|
DL E&C Co Ltd
KO:375500
|
$1.41 Billion |
|
Anupam Rasayan India Limited
NSE:ANURAS
|
$1.41 Billion |
|
Changzheng Engineering Co Ltd
SHG:603698
|
$1.41 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Absci Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 179,133,000 to 189,449,000, a change of 10,316,000 (5.8%).
- Net loss of 115,183,000 reduced equity.
- New share issuances of 105,835,000 increased equity.
- Other comprehensive income increased equity by 595,000.
- Other factors increased equity by 19,069,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-115.18 Million | -60.8% |
| Share Issuances | $105.83 Million | +55.86% |
| Other Comprehensive Income | $595.00K | +0.31% |
| Other Changes | $19.07 Million | +10.07% |
| Total Change | $- | 5.76% |
Book Value vs Market Value Analysis
This analysis compares Absci Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.04x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.45 | $11.13 | x |
| 2020-12-31 | $0.73 | $11.13 | x |
| 2021-12-31 | $3.95 | $11.13 | x |
| 2022-12-31 | $3.02 | $11.13 | x |
| 2023-12-31 | $1.91 | $11.13 | x |
| 2024-12-31 | $1.62 | $11.13 | x |
| 2025-12-31 | $1.39 | $11.13 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Absci Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -60.80%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4113.68%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.14x
- Recent ROE (-60.80%) is below the historical average (-38.33%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -319.61% | 0.11x | 0.00x | $-2.47 Million |
| 2020 | -21.42% | -300.27% | 0.05x | 1.32x | $-21.05 Million |
| 2021 | -27.58% | -2111.25% | 0.01x | 1.16x | $-137.57 Million |
| 2022 | -38.23% | -1825.37% | 0.02x | 1.17x | $-132.35 Million |
| 2023 | -62.76% | -1933.65% | 0.03x | 1.23x | $-128.18 Million |
| 2024 | -57.56% | -2274.06% | 0.02x | 1.19x | $-121.02 Million |
| 2025 | -60.80% | -4113.68% | 0.01x | 1.14x | $-134.13 Million |
Industry Comparison
This section compares Absci Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $120,016,867
- Average return on equity (ROE) among peers: -101.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Absci Corp (ABSI) | $246.13 Million | 0.00% | 0.09x | $1.41 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $29.61 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $4.06 Million | -282.32% | 0.21x | $248.75 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $15.18 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Arbutus Biopharma Corp (ABUS) | $59.19 Million | -23.76% | 0.21x | $834.03 Million |
| ABVC Biopharma Inc (ABVC) | $13.30 Million | -59.47% | 0.58x | $26.65 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $7.56 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $17.86 Million | -80.65% | 0.23x | $3.55 Billion |
About Absci Corp
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the… Read more